Supernus Pharmaceuticals (SUPN) Short term Debt (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 9 years of Short term Debt data on file, last reported at $31.1 million in Q4 2025.

• On a quarterly basis, Short term Debt fell 34.41% year-over-year to $31.1 million in Q4 2025; TTM through Dec 2025 was $31.1 million, a 34.41% decrease from a year earlier, with the FY2025 full-year figure at $31.1 million, down 34.41% from the prior year.
• Short term Debt for Q4 2025 stood at $31.1 million, up from $11.2 million in the prior quarter.
• Over the last five years, Short term Debt for SUPN reached as high as $78.4 million in Q1 2023 and fell as low as $11.2 million in Q3 2025.
• Historically, Short term Debt has averaged $39.4 million across 5 years, with a median of $45.9 million in 2023.
• Across the five-year window, Short term Debt jumped 146.54% in 2023 and tumbled 75.88% in 2025, its largest moves.
• Year by year, Short term Debt stood at $44.8 million in 2021, then sank by 52.9% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024, then plunged by 34.41% to $31.1 million in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $31.1 million in Q4 2025, $11.2 million in Q3 2025, and $30.0 million in Q1 2025.